CO - Global Cord Blood Corporation

NYSE - NYSE Delayed Price. Currency in USD
4.3200
-0.1200 (-2.70%)
At close: 4:02PM EST

4.3200 0.00 (0.00%)
After hours: 4:17PM EST

Stock chart is not supported by your current browser
Previous Close4.4400
Open4.4400
Bid4.3200 x 2200
Ask4.9000 x 800
Day's Range4.2900 - 4.4700
52 Week Range4.1400 - 7.7300
Volume96,304
Avg. Volume73,191
Market Cap525.1M
Beta (5Y Monthly)0.12
PE Ratio (TTM)14.74
EPS (TTM)0.2930
Earnings DateNov 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 30, 2018
1y Target Est15.00
  • Coronavirus update: 1,383 deaths, more than 63,000 sickened, Expedia predicts impact beyond Q1
    MarketWatch

    Coronavirus update: 1,383 deaths, more than 63,000 sickened, Expedia predicts impact beyond Q1

    There are more than 63,000 cases of COVID-19, the novel coronavirus that was first identified in December in Wuhan, China, and 1,383 deaths, according to the World Health Organization.

  • MarketWatch

    Global Cord Blood's stock rises as it predicts coronavirus impact

    Shares of Global Cord Blood Corp. were up 0.2% in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVID-19, the new coronavirus that has sickened at least 48,000 people, primarily in China. Global Cord Blood, which is an umbilical cord blood banking operator, attribution the projected impact to a combination of factors: some of its workers are not able to return to work due to travel restrictions; hospitals are restricting access to sales representatives, including those employed by Global Cord Blood; and the company's operating costs may rise because it has had to purchase additional medical supplies and equipment for its employees and clients. Global Cord Blood said in a news release that it may adjust its sales target for fiscal 2010 and its "strategy" for fiscal 2021. The company's stock is down 27% over the past year, while the S&P 500 has gained 22%.

  • PR Newswire

    Global Cord Blood Corporation Provides Update on Impact of Coronavirus

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today provided an update on the impact of the 2019 novel coronavirus ("2019-nCoV") on its operations.

  • PR Newswire

    Global Cord Blood Corporation Appoints Mr. Siu Chuen Cheng as Independent Non-executive Director

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr. Siu Chuen Cheng as a new independent non-executive director to the Board of Directors of the Company (the "Board").

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 27-Nov-19 1:00pm GMT

    Q2 2020 Global Cord Blood Corp Earnings Call

  • MarketWatch

    French regulator ends probe into supermarket Casino and short-seller Muddy Waters

    The French regulator, Autorité des Marchés Financiers, on Tuesday said it's concluded its investigation into both French supermarket chain Casino as well as the short-selling firm Muddy Waters. The regulator said it's sending what it calls letters of observations to both -- telling Casino, about the quality of financial information between 2013 and 2018, particularly in regard to property development. To Muddy Waters -- which earlier on Tuesday announced a new short position against NMC Health \-- the regulator said it stressed "the importance of compliance with the principles of honesty, fairness and impartiality that apply to any person issuing investment recommendations, including from abroad, where these recommendations involve securities admitted to trading on a regulated market and can be accessed from France." The AMF added that it will discuss its approach to shareholder activism in the first quarter of 2020.

  • Hedge Funds Have Never Been More Bullish On Global Cord Blood Corporation (CO)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Global Cord Blood Corporation (CO)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • PR Newswire

    PRC NHC Issues New Policy on Cord Blood Banks, Implementation Rules To Be Provided

    Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported that China's National Health Commission ("NHC") recently issued a new policy allowing the relevant Provincial Health Commissions ("PHCs") to approve cord blood bank licenses in 18 pilot Free Trade Zones ("FTZs") in China.

  • PR Newswire

    Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual General Meeting, which was held on December 5, 2019, in Hong Kong S.A.R., China.

  • PR Newswire

    Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2020 Financial Results

    Earnings Call Scheduled for 8:00 a.m. ET on November 27, 2019 HONG KONG , Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord ...

  • PR Newswire

    Global Cord Blood Corp Comments on New Regulation

    HONG KONG, Nov. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today commented on a new regulation related to companies in possession of human DNA information relating to the PRC. The Company is still in the process of evaluating the implications of the new regulation on the cord blood banking industry and its business. The Regulation of the People's Republic of China on the Administration of Human Genetic Resources (the "Regulation") has come into effect and the Company recently received an inquiry concerning its impact on the Company.

  • PR Newswire

    Global Cord Blood Corporation Appoints Mr. Jack Chow As an Independent Non-executive Director

    HONG KONG, Nov. 11, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of a new independent non-executive director to the Board of Directors of the Company (the "Board"). In order to further strengthen GCBC's Board composition and the Company's leadership position in China's evolving cord blood banking industry, the Board is delighted to announce that Mr. Jack Chow will join the Board as a class B independent non-executive director, effective immediately.

  • Were Hedge Funds Right About Warming Up To Global Cord Blood Corp (CO)?
    Insider Monkey

    Were Hedge Funds Right About Warming Up To Global Cord Blood Corp (CO)?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • PR Newswire

    The Committee for China Cord Fairness Announces Support From The Two Leading Proxy Advisory Firms for Proposals Seeking Minority Shareholder Protections and Governance Enhancements at Global Cord Blood Corporation

    Both ISS and Glass Lewis Support Conditioning All Business Transactions on Approval by a Majority of the Unaffiliated Shareholders ISS Notes "A number of governance shortcomings have been identified" ...

  • PR Newswire

    Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 5, 2019

    HONG KONG, Sept. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2019 annual general meeting of shareholders at its Hong Kong office located at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 5, 2019 (8:00 a.m. U.S. Eastern Standard Time on December 5, 2019).

  • Thomson Reuters StreetEvents

    Edited Transcript of CO earnings conference call or presentation 28-Aug-19 12:00pm GMT

    Q1 2020 Global Cord Blood Corp Earnings Call

  • Global Cord Blood Corporation (CO) Q1 2020 Earnings Call Transcript
    Motley Fool

    Global Cord Blood Corporation (CO) Q1 2020 Earnings Call Transcript

    CO earnings call for the period ending June 30, 2019.